Mobile Menu

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us
  • Menu
  • Skip to primary navigation
  • Skip to main content

https://eyecro.com

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us

Preclinical Ophthalmic Contract Research

EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities.  Our models are well established and optimized to facilitate generation of reproducible datasets with meaningful endpoints.
With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals.  We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS™.

  • injection
  • micron
  • 5G2A9841
  • 5G2A9861
  • 5G2A9931
  • ideas
  • 5G2A0010
  • erg
  • Companies Serviced by EyeCRO 2022
  • okt
  • ded
  • goggles
  • slide
  • cnv

The Global Leader in Preclinical Ophthalmic Research

Microemulsion Drug Ocular Penetration System MiDROPS™

MiDROPS™ was developed to allow for eyedrop formulation of small molecules that are lipophilic.  This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable.  These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment.  Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.

midrops vials

Click here to learn more about this innovative platform technology

Models

Allergic Conjunctivitis

Corneal Sensitivity

Corneal Wound Healing

Diabetic Keratopathy

DL-AAA Retinal Leakage

Dry Eye Disease

Endotoxin induced Uveitis

Experimental Autoimmune Uveitis

Geographic Atrophy

Inherited Retinal Degenerations

Ischemia Reperfusion Injury

Laser-induced Choroidal Neovascularization

Light Damaged

Optic Nerve Crush

Oxygen Induced Retinopathy

Retinal Detachment

Retinal Vein Occlusion

Mitochondrial Neuropathy

STZ-induced Diabetic Retinopathy

VEGF-induced permeability

Capabilities

Bioanalytical Detection

Biochemistry

Histology

Ophthalmic Imaging and Physiology

News & Events

EyeCRO scientists contribute to paper published in Biology

Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more

EyeCRO scientists contribute to paper published in BiologyRead More

EyeCRO scientists contribute to study published in Experimental Eye Research

Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more

EyeCRO scientists contribute to study published in Experimental Eye ResearchRead More

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic CannabinoidsRead More

EyeCRO scientists contribute to study published in Nature

“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The…

EyeCRO scientists contribute to study published in NatureRead More

Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?

“Anti-vascular endothelial growth factor (anti-VEGF) medications have a proven track record in treating diabetic macular edema (DME). However, researchers continue to investigate whether these medications can be made more efficient and cost-effective.” “Both the RETAIN[1] and REACT[2] studies showed that…

Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?Read More

New Age-Related Macular Degeneration Common in Untreated Fellow Eyes

“NEW YORK (Reuters Health) – New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the…

New Age-Related Macular Degeneration Common in Untreated Fellow EyesRead More

View All Posts

EyeCRO on Twitter

[custom-twitter-feeds]

Contact Us

pen and post it

EyeCRO – Headquarters

5301 N. Beverly Drive
Oklahoma City, OK 73105

EyeCRO – Ann Arbor

2725 S. Industrial Hwy, Suite 150
Ann Arbor, MI 48104

info@eyecro.com

Request more information

  • This field is for validation purposes and should be left unchanged.

© 2023 · EyeCRO · All Rights Reserved.